-
Atmo awarded Stage 2 funding through ANDHealth+ program.
14 October 2024. Atmo Biosciences is pleased to announce that it has been awarded funding through the ANDHealth+ Stage 2 Commercialization Program, aimed at helping five digital health companies scale...
-
Atmo Gas Capsule used in Florida State University study assessing gastrointestinal impact of a fasting diet
May 2, 2024. Clinical Research. Atmo Biosciences’ ingestible gas-sensing capsule was used to assess the impact of an early-time restricted eating diet on gastrointestinal hydrogen production and gas...
-
Atmo Biosciences reaches primary endpoints in pivotal clinical study for initial indication
April 9, 2024. Atmo Biosciences is delighted to report that it has successfully reached its primary endpoints in a pivotal clinical study to assess whole and regional gut transit time in subjects with...
December 14, 2023
Atmo Biosciences achieves patient recruitment target for dysmotility pivotal clinical study.
Atmo Biosciences has reached its patient recruitment target ahead of schedule for its dysmotility pivotal clinical study.
November 13, 2023
Atmo Biosciences and RMIT University granted Japanese Patent for ingestible gas-sensing capsule.
Atmo Biosciences is pleased to announce that the Japan Patent Office has granted a patent related to key intellectual property for Atmo’s ingestible gas-sensing capsule.
October 26, 2023
Atmo Biosciences partners with ps.healthcare to expand Machine Learning (ML) and Artificial Intelligence (AI) capabilities.
Atmo Biosciences today announced it is partnering with ps.healthcare to shape its data strategy, and create a roadmap of future applications using machine learning (ML) and artificial intelligence (AI).
October 19, 2023
Study indicates Atmo Gas Capsule could be used to evaluate duodeno-gastric reflux in dysmotility patients.
The Atmo Gas Capsule could be used to help understand and monitor duodeno-gastric reflux and provide insight into its connection to delayed gastric emptying, according to an investigation by researchers from Monash University and Western Sydney University.
October 3, 2023
Atmo Biosciences reaches 60 per cent recruitment target in dysmotility pivotal clinical study.
Atmo Biosciences has reached 60 per cent of its recruitment target for a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.
September 25, 2023
Breakthrough Victoria announces investment in Atmo Biosciences to help people with gut disorders.
Breakthrough Victoria today announced it has invested in Atmo Biosciences to support the commercialization of the company’s world-first ingestible gas-sensing capsule that can help diagnose functional gastrointestinal disorders (FGIDs), which affect almost 40 per cent of Australians1.
August 25, 2023
Atmo Biosciences selected into ANDHealth+ commercialization program to help scale its products nationally and internationally.
Atmo Biosciences is one of only five businesses accepted into the market-leading ANDHealth+ commercialization program, which helps digital health companies to scale their products nationally and internationally.
August 10, 2023
Atmo Biosciences recruits first patients in dysmotility pivotal clinical study
Atmo Biosciences today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.
The study involves simultaneous ingestion of the Atmo Gas Capsule and predicate device SmartPill to demonstrate the ability of Atmo’s gas-sensing capsule to assess whole and regional gut transit. Clinicians evaluate regional gut transit to help diagnose motility disorders such as gastroparesis (delayed emptying from the stomach), and slow transit constipation (slow transit through the colon).
May 15, 2023
Results presented at DDW show Atmo Gas Capsule can be used to assess whole gut transit time in patients with dysmotility
A Western Sydney University (WSU) and Monash University comparative study has validated the Atmo Gas Capsule relative to the SmartPill when measuring gastric emptying time and colonic transit time in patients with gastroparesis and chronic constipation. Dr Jerry Zhou, lecturer and clinical researcher at WSU School of Medicine, presented findings from the study in a poster presentation at Digestive Disease Week (DDW), held May 6-9 in Chicago.
May 1, 2023
Atmo Biosciences appoints world-renowned gastroenterologist Professor Eamonn Quigley as Medical Advisory Board Chair
Prof. Quigley is David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology at Houston Methodist Hospital in Texas. He is internationally known for his research on gastrointestinal motility disorders, particularly irritable bowel syndrome (IBS) and its link to the gut microbiome. As Atmo MAB Chair, Prof. Quigley will provide leadership and guidance regarding Atmo’s clinical trials portfolio.
April 17, 2023
Atmo Biosciences strengthens U.S. focus with new board appointment and establishment of San Diego office
Atmo Biosciences is strengthening its U.S. focus with the appointment of experienced medical device executive Chris Bertrand to the Atmo Board and establishment of a San Diego, California office.
The increased presence in the U.S. comes as Atmo Biosciences prepares to begin a multi-site pivotal study to support a U.S. Food and Drug Administration (FDA) submission around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility.
March 30, 2023
Atmo Biosciences closes fully subscribed $8 million Series B funding round
Atmo Biosciences has raised A$8 million in a fully subscribed Series B funding round.
The raise was led by Japanese multinational company Otsuka Pharmaceutical, an existing strategic shareholder that took up more than its pro rata entitlement.
